Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit
Thursday, September 12, 2024
Eliem Therapeutics, Inc., announced today members of the management team will participate at the Stifel 2024 Virtual Immunology and Inflammation Summit being held September 17-18, 2024.
Stifel 2024 Virtual Immunology and Inflammation Summit
Date: Wednesday, September 18, 2024
Format: 1x1 meetings
About Eliem Therapeutics, Inc.
Eliem Therapeutics is focused on developing therapeutics for autoimmune-driven inflammatory diseases, including advancing budoprutug, an anti-CD19 antibody designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia and membranous nephropathy. For more information, please visit https://eliemtx.com/.
Investors
Chris Brinzey
ICR Westwicke
chris.brinzey@westwicke.com
339-970-2843
Source: globenewswire.com
